Hoffmann-la Roche

This study is testing a new under-the-skin injection version of the MS drug ocrelizumab in children and teenagers aged 10 to 18. The main goals are to see how the drug moves through the body, if it's safe, and how it affects the immune system. Participants will receive the drug f…

This early-stage study is testing the safety of an experimental gene therapy called SPK-8011QQ in adult men with severe hemophilia A. The main goal is to see if the treatment is safe and well-tolerated, not to prove it works. Researchers will carefully monitor five participants f…

This study is testing whether a new preventive drug called NXT007 works better than the current standard treatment, emicizumab, at reducing bleeding episodes in people with hemophilia A. It will involve 360 participants aged 12 and older who have moderate to severe hemophilia, wi…

This early-stage study is testing a new targeted radiation therapy for people with metastatic colorectal cancer that has stopped responding to standard treatments. The therapy uses radioactive particles that specifically seek out and attach to cancer cells. Researchers will first…

This study is testing a new drug called afimkibart to see if it can help children aged 2 to 17 who have moderate to severe Crohn's disease. The goal is to control the disease by reducing gut inflammation and symptoms in kids who haven't gotten enough help from other treatments. R…

This study aims to see if a new preventive treatment called NXT007 works better and is as safe as the current standard factor VIII injections for people with moderate or severe hemophilia A. It will involve about 126 people aged 12 and older who are already using factor VIII to p…

This study is testing whether a new experimental drug called RO7771950 works better than the current standard treatment (tucatinib) for advanced HER2-positive breast cancer that has spread or is hard to treat. Both drugs are given with two other cancer medications (trastuzumab an…

This study aims to collect real-world information from 3000 people with COPD who experience frequent flare-ups. It will track their disease course, treatments, and quality of life over time to better understand patient and caregiver experiences. The goal is to gather knowledge to…